Abstract
Dementia in individuals with Down syndrome (DS) is the leading cause of early-onset cognitive decline occurring before the age of 50. However, establishing an accurate diagnosis remains particularly challenging due to pre-existing intellectual disability, variability in baseline cognitive function, and the limited reliability of standard neuropsychological assessments. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) plays a critical role in identifying underlying neurodegenerative processes and supporting the diagnosis. We present a case of DS with multiple known and unknown pathologies identified on brain 18F-FDG PET and a confirmed diagnosis of early-onset mild Alzheimer’s disease.
Keywords:
18F-FDG, dementia, Alzheimer, Down syndrome
Ethics
Informed Consent: The written and verbal informed consent was obtained from the patient and his custodian.
Authorship Contributions
Surgical and Medical Practices: E.A., Concept: E.A., S.M., Design: E.A., S.M., Data Collection or Processing: E.A., Analysis or Interpretation: E.A., S.M., Literature Search: E.A., Writing: E.A.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.
References
1
Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C; MEADOWS trial researchers. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:528-536.
2
Arriola-Infante JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, Vaqué-Alcázar L, Rozalem-Aranha M, Arranz J, Rodríguez-Baz Í, Maure-Blesa L, Videla L, Barroeta I, Del Hoyo Soriano L, Benejam B, Fernández S, Sanjuan-Hernández A, Giménez S, Alcolea D, Belbin O, Flotats A, Camacho V, Lleó A, Carmona-Iragui M, Fortea J, Bejanin A. Regional brain metabolism across the Alzheimer’s disease continuum in Down syndrome. Ann Neurol. 2025;98:163-173.
3
Neale N, Padilla C, Fonseca LM, Holland T, Zaman S. Neuroimaging and other modalities to assess Alzheimer’s disease in Down syndrome. Neuroimage Clin. 2017;17:263-271.
4
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
5
Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology. 1996;198:837-843.
6
Andersson JL, Vagnhammar BE, Schneider H. Accurate attenuation correction despite movement during PET imaging. J Nucl Med. 1995;36:670-678.
7
Huang SC, Hoffman EJ, Phelps ME, Kuhl DE. Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. J Comput Assist Tomogr. 1979;3:804-814.
8
Kyme AZ, Fulton RR. Motion estimation and correction in SPECT, PET and CT. Phys Med Biol. 2021;66.
9
Sabbagh MN, Chen K, Rogers J, Fleisher AS, Liebsack C, Bandy D, Belden C, Protas H, Thiyyagura P, Liu X, Roontiva A, Luo J, Jacobson S, Malek-Ahmadi M, Powell J, Reiman EM. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer’s dementia. Alzheimers Dement. 2015;11:994-1004.
